Volume 15, Issue 3 (August 2012)                   J Arak Uni Med Sci 2012, 15(3): 49-57 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Moaya M, Ziaei S, Faghih zaheh S. Effect of tibolone and hormone therapy on body composition and fat distribution in postmenopausal women. J Arak Uni Med Sci. 2012; 15 (3) :49-57
URL: http://amuj.arakmu.ac.ir/article-1-646-en.html
profesor tarbiat modares university , ziaei_sa@modares.ac.ir
Abstract:   (8589 Views)
Background: Menopause is associated with changes in body composition in postmenopausal women. The aim of this study was to compare the effects of tibolone and continuous combined hormone therapy (HT) on body composition in postmenopausal women. Materials and Methods: In this randomized clinical trial, 120 menopausal women were randomly selected and divided into three groups. Of these, 40 women received 2.5 mg tibolone plus one Cal+D tablet (500 mg carbonate calcium with 200 IU vitamin D) daily, 40 women received 0.625 mg conjugated estrogen combined with 2.5 mg medroxy progesterone acetate plus one Cal+D tablet daily and the rest 40 (the control group) only received one Cal+D tablet daily. All regimes continued for nine months. Body composition was evaluated with measurements of waist to hip ratio (WHR), fat mass (FM), fat-free mass (FFM), body mass index (BMI), and weight before and after intervention. Fat mass and fat free mass were assessed by measurement of skin-fold thickness. Data were analyzed by SPSS software. Results: In the tibolone group, FFM, BMI, and weight significantly increased compared to the baseline (p<0.05). In the HT group, only weight and BMI significantly increased (p<0.05). In the control group, however, BMI, FM, and weight did not significantly increase in comparison with the other groups. Overall, tibolone group showed a more significant increase in comparison with the other groups (p<0.01) Conclusion: From these results, it can be concluded that tibolone can be used in treating menopausal changes in menopausal women as an alternative to continuous combined hormone therapy.
Full-Text [PDF 214 kb]   (1643 Downloads)    
Subject: Obstetrics & Gynocology
Received: 2010/03/3

Add your comments about this article : Your username or Email:

Send email to the article author

© 2018 All Rights Reserved | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb